Use of recombinant activated factor VII to treat the acquired coagulopathy of trauma.
Recombinant activated factor VII (rFVIIa) is a drug commonly utilized in the treatment of patients with hemophilia and inhibitors. However, its use in previously normal patients with an acquired coagulopathy after trauma and surgery is increasing. Multiple trauma case reports and several case series are available, lending support for the efficacy of the drug in reversing the coagulopathy of trauma. Data from six large animal studies evaluating the efficacy in trauma models are available for evaluation. A single prospective randomized study in elective surgery has recently been published, documenting reduced blood loss and decreased transfusion after a single preoperative dose. This review describes those studies and reiterates the need for well designed prospective randomized human trauma studies.
Holcomb
John B
JB
Trauma Division, United States Army Institute of Surgical Research, San Antonio, TX 78234-6315, USA. john.holcomb@amedd.army.mil
D000818:Animals; D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D016063:Blood Loss, Surgical; D005078:Exchange Transfusion, Whole Blood; D015942:Factor VIIa / Q000627:therapeutic use*; D006488:Hemostasis, Surgical; D006801:Humans; D007036:Hypothermia, Induced; D011994:Recombinant Proteins / Q000627:therapeutic use*; D014947:Wounds and Injuries / Q000150:complications* / Q000601:surgery
D011994:Recombinant Proteins; D015942:Factor VIIa